Close Menu

NEW YORK – Ortho Clinical Diagnostics on Thursday announced that Health Canada has approved its next-generation Vitros High Sensitivity Troponin I assay, a critical tool for clinicians seeking improved strategies to more rapidly and accurately identify patients suffering from a heart attack. The firm said it is launching the assay in Canada.

The latest addition to Ortho's cardiology menu, the assay also aids in identifying low-risk patients who may be safely discharged to help reduce the cost of care and alleviate the burden on hospital resources, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.